Technologies for Detecting Tumor-Derived Cell Clusters
ID: NIH/NCI 457Type: BOTH
Overview

Topic

Technologies for Detecting Tumor-Derived Cell Clusters

Agency

Department of Health and Human ServicesNational Institutes of Health

Program

Type: SBIRPhase: BOTHYear: 2023

Topic Link

https://www.sbir.gov/node/2451705

Additional Information

https://sam.gov/opp/aa72581c848947f0b61c15062e604862/view
Timeline
  1. 1
    Release Aug 25, 2023 12:00 AM
  2. 2
    Open Aug 25, 2023 12:00 AM
  3. 3
    Next Submission Due Nov 14, 2023 12:00 AM
  4. 4
    Close Nov 14, 2023 12:00 AM
Description

The National Institutes of Health (NIH) and The Centers for Disease Control and Prevention (CDC) are seeking proposals for technologies that can detect tumor-derived cell clusters. These clusters play a crucial role in metastasis and have been shown to have a higher metastatic potential than individual circulating tumor cells (CTCs). The goal is to develop technologies that can assess metastatic risk early and facilitate prompt interventions, ultimately improving cancer outcomes. The solicitation is open to Fast-Track proposals, with a total of 3-5 anticipated awards. The budget for Phase I is up to $400,000 for up to 12 months, and for Phase II, it is up to $2,000,000 for up to 2 years. Proposals exceeding the budget or project duration may not be funded. The current status of the solicitation is closed. The biology of tumor-derived cell clusters is poorly understood, and there is a need for technologies that can enrich, enumerate, and analyze these clusters to better understand their role in metastasis.

Files
No associated files provided.
Similar Opportunities
Industrialization and Translation of Extracellular Vesicles for use in Regenerative Medicine (UT1/UT2) Clinical Trial Not Allowed
Active
Department of Health and Human Services
The Department of Health and Human Services, specifically the National Institutes of Health, is seeking proposals for the industrialization and translation of extracellular vesicles (EVs) for use in regenerative medicine. EVs are membrane-enclosed carriers of bioactive substances that are used for intercellular communication. This funding opportunity aims to support the development of novel EV-based therapeutic platforms for tissue and organ repair in regenerative medicine. The focus is on the production, manufacturing, and use of native or engineered EVs as therapeutics. The goal is to address challenges in the field, such as the production of sufficient quantities of EVs, labor-intensive isolation procedures, and non-specific isolation methodologies. The funding opportunity is open for both Phase I and Phase II (Fast track) grant applications. Phase I applications should focus on feasibility and therapeutic applications, while Phase II applications should optimize and scale-up technology platforms. The validation of therapeutic benefits is required for Phase II applications. The funding opportunity prioritizes IND enabling therapeutic platforms that have the potential for regulatory approval and commercialization. Applicants are encouraged to engage with regulatory authorities and address the expected commercial impact of their proposed technology platform. The application due dates are June 6, 2023, June 6, 2024, and June 6, 2025. For more information, visit the solicitation agency URL: [link](https://grants.nih.gov/grants/guide/PA-files/PAR-23-268.html).
Miniaturization and Automation of Tissue Chip Systems (MATChS) (U43/U44 Clinical Trial Not Allowed)
Active
Department of Health and Human Services
The Department of Health and Human Services, specifically the National Institutes of Health, is seeking proposals for the Miniaturization and Automation of Tissue Chip Systems (MATChS) through their SBIR program. The goal of this funding opportunity is to support the development of benchtop, portable, automated systems that maintain 3D tissue constructs and provide biologically relevant outputs of tissue health and function. The technology should be easy to use, have integrated in-line sensors, and be capable of rapid and reproducible high-throughput analysis. The system should also be capable of maintaining culture without external intervention and be remotely monitored through real-time biosensing. The fabrication procedure must be cost-effective, mass producible, and robust. The funding opportunity is open for Phase I, Phase II, Fast-Track, and Direct to Phase II grant applications. The project duration is from 2024 to 2026, with multiple application due dates. More details can be found on the grants.gov website.
Miniaturization and Automation of Tissue Chip Systems (MATChS) (U43/U44 Clinical Trial Not Allowed)
Active
Department of Health and Human Services
The Department of Health and Human Services, specifically the National Institutes of Health, is seeking proposals for the Miniaturization and Automation of Tissue Chip Systems (MATChS) through their SBIR program. The goal of this funding opportunity is to support the development of benchtop, portable, automated systems that maintain 3D tissue constructs and provide biologically relevant outputs of tissue health and function. The technology should be easy to use, have integrated sensors, and enable rapid and reproducible high-throughput analysis. The project should also focus on automation and miniaturization, with the potential for remote monitoring and real-time biosensing. The funding opportunity is open for Phase I, Phase II, Fast-Track, and Direct to Phase II grant applications. The project duration spans multiple years, with application due dates in February of each year. More information can be found on the grants.gov website.
Industrialization and Translation of Extracellular Vesicles for use in Regenerative Medicine (UT1/UT2) Clinical Trial Not Allowed
Active
Department of Health and Human Services
The Department of Health and Human Services, specifically the National Institutes of Health, is seeking proposals for the industrialization and translation of extracellular vesicles (EVs) for use in regenerative medicine. EVs are membrane-enclosed carriers of bioactive substances that are used for intercellular communication. This funding opportunity aims to support the development of novel EV-based therapeutic platforms for tissue and organ repair in regenerative medicine. The focus is on the production, manufacturing, and use of native or engineered EVs as therapeutics. The goal is to address challenges in the field, such as the production of sufficient quantities of EVs, labor-intensive isolation procedures, and non-specific isolation methodologies. The funding opportunity is open for both Phase I and Phase II (Fast track) grant applications. Phase I applications should focus on feasibility and therapeutic applications, while Phase II applications should optimize and scale-up technology platforms. The validation of therapeutic benefits is required for Phase II applications. The funding opportunity prioritizes IND enabling therapeutic platforms that have the potential for regulatory approval and commercialization. Applicants are encouraged to engage with the FDA Center for Biologics Evaluation and Research for regulatory guidance. The application deadline is June 6th, 2023, with subsequent deadlines in 2024 and 2025. More information can be found on the grants.gov website.
Industrialization and Translation of Extracellular Vesicles for use in Regenerative Medicine (U43/U44 Clinical Trials Not Allowed)
Active
Department of Health and Human Services
The Department of Health and Human Services, specifically the National Institutes of Health, is seeking proposals for the industrialization and translation of extracellular vesicles (EVs) for use in regenerative medicine. EVs are membrane-enclosed carriers of bioactive substances that play a role in intercellular communication. This funding opportunity aims to support the development of novel EV-based therapeutic platforms for tissue and organ repair in regenerative medicine. The focus is on the production, manufacturing, and use of native or engineered EVs as therapeutics. The goal is to address challenges in the field, such as large-scale production and manufacturing of EVs for therapeutic use. The funding opportunity is open to small business concerns and offers both Phase I and Phase II grants. Phase I applications should focus on feasibility and therapeutic applications, while Phase II applications should optimize and scale-up technology platforms. The validation of therapeutic benefits is required for Phase II applications. The development of IND enabling therapeutic platforms that can work towards regulatory approval and commercialization is prioritized. Applications must include project milestones and should align with the goals of the funding opportunity. The application due dates are June 6th of each year from 2023 to 2025. For more information, visit the solicitation agency URL: [link](https://grants.nih.gov/grants/guide/PA-files/PAR-23-267.html).